(Q46260498)

20 December 2017

title

Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response (English)

1 reference

20 December 2017

1 reference

Ronald van Vollenhoven

5

object named as

Ronald F van Vollenhoven

0 references

author name string

Thórunn Jónsdóttir

1

1 reference

20 December 2017

Agneta Zickert

2

1 reference

20 December 2017

Birgitta Sundelin

3

1 reference

20 December 2017

Elisabet W Henriksson

4

1 reference

20 December 2017

Iva Gunnarsson

6

1 reference

20 December 2017

publication date

3 January 2013

1 reference

20 December 2017

published in

Rheumatology

1 reference

20 December 2017

volume

52

1 reference

20 December 2017

issue

5

1 reference

20 December 2017

page(s)

847-855

1 reference

20 December 2017

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

cites work

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Assessment of a lupus nephritis cohort over a 30-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Current treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project".

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Estimation of glomerular filtration rate in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Prognostic factors in lupus nephritis. Contribution of renal histologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

European consensus statement on the terminology used in the management of lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Do self-perpetuating B lymphocytes drive human autoimmune disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES348

10.1093/RHEUMATOLOGY/KES348

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017